GRAL GRAIL, Inc.
USHealthcareAs of 2026-07-10 13:36
Why GRAL matters now
GRAIL, Inc. (GRAL) is a US stock in Healthcare. The latest InvestLog snapshot shows $71.30 with -5.93% on the session and $3.06B in market capitalization; recent performance reads 1-month +4.51% and YTD -25.53%.
The latest financial table shown here is Q1 2026, with revenue of $40.8M, net income of $-93.2M, and EPS of $-2.29. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.7%.
The latest indexable market news headline is "ROSEN, SKILLED INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GRAL" from Newsfile Corp.
Additional event context on this page matters because analyst consensus is Hold with a median target of $60.00; recent insider activity includes Partridge Andrew John filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.04
P/S
17.52
EV/EBITDA
-8.04
DCF Value
$-37.54
FCF Yield
-10.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-14.8%
Operating Margin
-348.7%
Net Margin
-253.2%
ROE
-16.4%
ROA
-14.1%
ROIC
-15.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $40.8M | $-93.2M | $-2.29 |
| Q4 2025 | $43.6M | $-99.2M | $-2.44 |
| FY 2025 | $147.2M | $-408.4M | $-11.11 |
| Q3 2025 | $36.2M | $-89.0M | $-2.46 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$73.43
Target (Median)
$60.00
Target Range
$56.00 - $130.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
3.15
GRAIL, Inc. is a biotechnology firm dedicated to advancing innovations for detecting cancer at its earliest stages. Among its key offerings is Galleri, a screening test designed for individuals aged 50 and above who show no symptoms of the disease. GRAIL also offers DAC (Diagnostic Aid for Cancer), which assists in expediting the diagnostic process for patients where cancer is clinically suspected. Additionally, the company is actively engaged in the development of minimal residual disease (MRD) tests and various other post-diagnosis solutions. Established in 2015 with its headquarters in Menlo Park, California, GRAIL, Inc. previously operated as a subsidiary of Illumina, Inc.